Rugiet Adds Additional Physician-Prescribed, Pharmaceutical-Grade Peptides for Patients
Rugiet Adds Additional Physician-Prescribed, Pharmaceutical-Grade Peptides for Patients
The men’s health company is applying its proven infrastructure, medical oversight, and procedures to new peptide offerings produced by 503A compounded pharmacies
Key Facts:
- What: Men’s health company Rugiet launched four new physician-prescribed peptide therapies to its portfolio: BPC-157, TB-500, Semax, and MOTS-c.
- How it Works: Licensed physicians prescribe peptides to qualifying patients, which are fulfilled through licensed U.S. 503A compounded pharmacies.
- Safety: Each batch is rigorously tested for purity, potency, and sterility for injectables prior to shipment. All Active Pharmaceutical Ingredients are for human pharmaceutical use, and come with a Certificate of Analysis.
- More Information: Rugiet.com/peptides
AUSTIN, Texas--(BUSINESS WIRE)--Rugiet, the men’s health company serving more than 700,000 patients, today announced the availability of four new physician-prescribed peptide therapies: BPC-157, TB-500, MOTS-c, and Semax. The announcement follows the U.S. Department of Health and Human Services’ (HHS) policy that states certain peptides can be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. The new peptides expand the company’s existing longevity and peptide portfolio, which includes Glutathione, Sermorelin, and NAD+.
“We’re building the most trusted, physician-led standard in a category that desperately needs one,” said Mike Apostal, CEO of Rugiet. “Every Rugiet patient gets a medical evaluation before anything is prescribed, and some will be told ‘no.’ Patients deserve to have someone in their corner who is truly advocating for their health.”
Rugiet’s prescription protocols are built on a physician-led model developed by its Medical Advisory Board, composed of leading experts in health and longevity, including Dr. Alex Tatem and Dr. Thomas Nabity. Every patient completes a medical intake, and a licensed physician reviews it to determine eligibility. Peptides are compounded by state-licensed U.S. 503A pharmacies from ingredients intended for human pharmaceutical use with a Certificate of Analysis (COA) and undergo additional testing by Rugiet to verify purity, potency, and sterility for injectables. Patients have ongoing support from Rugiet’s clinical team for questions, assessments, protocol adjustments, and access to labs tracking more than 130 health signals.
“Peptides have never been hard to find,” said Dr. Alex Tatem, a board-certified urologist and member of Rugiet’s Medical Advisory Board. “But for years, it’s been impossible to know what was actually in the vial. At Rugiet, the compounding is done by licensed 503A pharmacies that operate independently of the company, and then Rugiet has the finished batches tested again on top of what the pharmacy already did. So when patients pursue peptide therapy with Rugiet, they can have confidence they’re receiving the highest standard of care possible.”
Rugiet’s longevity and peptide offerings include:
- BPC-157 for supporting recovery and tissue repair
- TB-500 for supporting tissue repair
- Semax for supporting mental clarity and focus
- MOTS-c for supporting cellular energy and metabolic health
- NAD+ for supporting cellular energy restoration
- Glutathione for supporting cellular defense
- Sermorelin for supporting recovery, muscle performance, and sleep quality
Frequently Asked Questions
What peptides did Rugiet add?
Rugiet added four new peptides: BPC-157, TB-500, Semax, and MOTS-c. These peptides are now added to Rugiet’s existing longevity and peptide portfolio, which includes Sermorelin, Glutathione, and NAD+.
Why did Rugiet begin selling new peptides?
The additions follow the U.S. Department of Health and Human Services’ October 30, 2026 policy for certain peptide compounding under section 503A.
Are peptides FDA-approved?
The HHS policy is an enforcement discretion policy under section 503A. It is not FDA approval of Rugiet’s peptides or of any peptide for any use.
Do I need a prescription?
Yes, every Rugiet patient completes a mandatory medical intake that is verified and reviewed by a licensed physician.
What is Rugiet doing to verify the quality of peptides?
Rugiet works with licensed U.S. 503A compounding pharmacies that source ingredients intended for human pharmaceutical use. Each ingredient lot comes with a Certificate of Analysis (COA), and pharmacy records that link ingredient lots to finished medications. Rugiet also arranges independent batch testing of finished products for purity, potency, and sterility for injectables.
What is the difference between research only peptides and pharmaceutical use peptides?
Research-only use sellers don’t require a prescription, physician oversight, or pharmacy fulfillment, and they do not provide medical guidance on dosing or safety. Rugiet requires a physician-reviewed medical intake, works with licensed pharmacies, and provides ongoing access to a clinical care team.
How do the labs fit into peptide treatment?
Rugiet’s Comprehensive Lab Panel tracks more than 130 health signals, giving your physician a deeper understanding of your health and helping inform whether peptide treatment is appropriate for you. Follow-up testing helps your physician track changes in relevant biomarkers and, alongside your symptoms and progress, guide adjustments to your care over time.
About Rugiet
Rugiet is a men’s health company that has combined clinical authority with personalized treatments since 2020 to help more than 700,000 patients take control of their health. From sexual health and sleep, to weight management, testosterone, and longevity, Rugiet focuses on helping men optimize their health at every age. Learn more at www.rugiet.com.
Contacts
For More Information:
Melissa Rubenstein
Between Us
melissa@thisisbetween.us

